title: Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab. Evidence for disease heterogeneity.
authors.forename: Verena I
authors.initials: VI
authors.lastname: Leussink
authors.forename: Helmar C
authors.initials: HC
authors.lastname: Lehmann
authors.forename: Gerd
authors.initials: G
authors.lastname: Meyer zu Hörste
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Hartung
authors.forename: Olaf
authors.initials: O
authors.lastname: Stüve
authors.forename: Bernd C
authors.initials: BC
authors.lastname: Kieseier
mesh_terms: D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000473:pathology; D000069442:Natalizumab; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000069442:Natalizumab; D000069283:Rituximab